On November 10, 2016 AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience reported financial results for the third quarter ended September 30, 2016 (Press release, AstraZeneca, NOV 10, 2016, View Source [SID1234516459]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Total worldwide product sales for the third quarter of 2016 was $ 5,025 million USD in comparison to that of $5,850 million USD for the third quarter of 2015. Total oncology product sales increased from $ 728 million USD in the third of 2015 to $867 million USD in the third quarter of 2016.

Regional sales for the third quarter of 2016 equated to; US – $1,538 m USD, Europe -$1,265 m USD, Established ROW- $827 m USD and Emerging markets – $1,395 m USD. Total regional sales of oncology products were; US- $237 m USD, Europe – $187 m USD, Established ROW – $216 m USD and $227 m USD in Emerging Markets.

For AstraZeneca’s detailed sales figures, visit: View Source(FINAL).v2.pdf

View Source